STAU1 Antibody

What are the key characteristics of STAU1 protein that researchers should know?

STAU1 is a ubiquitously expressed RNA-binding protein encoded by the STAU1 gene. It exists in multiple isoforms due to alternative splicing, with the two predominant isoforms being STAU1^55 and STAU1^63 (55 kDa and 63 kDa respectively) . STAU1 contains multiple double-stranded RNA-binding domains (dsRBDs) that enable it to bind to double-stranded RNA regardless of the sequence . It plays essential roles in:

• RNA transport and localization

• Translation regulation

• Staufen-mediated mRNA decay (SMD)

• Formation of ribonucleoprotein complexes

• Neuronal dendritic mRNA transport and synaptic plasticity

STAU1 can undergo liquid-liquid phase separation (LLPS) to form dynamic condensates in cells, which is crucial for its function in regulating RNA metabolism .

What applications are STAU1 antibodies commonly used for in research?

Based on the validation data from multiple commercial antibodies, STAU1 antibodies have been successfully used in numerous applications:

For optimal results, it's recommended to titrate the antibody concentration for each specific experimental system .

How can I validate the specificity of a STAU1 antibody?

To ensure antibody specificity for STAU1, implement the following validation strategies:

• siRNA knockdown: Transfect cells with STAU1-specific siRNA and control siRNA. A specific antibody should show decreased signal in STAU1-knockdown samples compared to controls. For example, studies have shown that transfection of siRNA-STAU1 in hippocampal neurons effectively down-regulates endogenous Stau1 expression as determined by immunofluorescence .

• Molecular weight verification: Confirm detection at the expected molecular weights of 55 kDa and 63 kDa, which correspond to the two major isoforms of STAU1 .

• Cross-reactivity assessment: Test antibody specificity by ensuring it doesn't detect related proteins like STAU2. Research has shown that siRNA-STAU1 does not affect Stau2-HA expression, confirming specificity for STAU1 .

• Positive and negative controls: Include tissues or cell lines known to express STAU1 (such as brain tissue, K-562 cells) as positive controls, and consider using STAU1-knockout cell lines as negative controls .

What are the recommended conditions for detecting STAU1 by Western blot?

Optimized Western blot protocol for STAU1 detection:

• Sample preparation: For tissue samples, homogenize in RIPA buffer with protease inhibitors. For cellular samples, lyse directly in sample buffer or RIPA buffer.

• Protein separation: Use 8-12% SDS-PAGE gels for optimal separation of the 55 kDa and 63 kDa isoforms.

• Transfer and blocking: Transfer to PVDF membranes and block with 5% non-fat milk in TBST.

• Antibody incubation:

  • Primary antibody: Dilute STAU1 antibody at 1:500-1:3000 for polyclonal antibodies or 1:1000 for monoclonal antibodies

  • Secondary antibody: Use appropriate HRP-conjugated or fluorescently-labeled secondary antibody

• Detection: Both isoforms (55 kDa and 63 kDa) should be detectable, though the relative abundance may vary by cell type .

• Controls: Include positive controls such as human brain tissue, K-562 cells, or mouse brain tissue, where STAU1 expression has been well-documented .

How can I optimize immunoprecipitation experiments with STAU1 antibodies?

For successful STAU1 immunoprecipitation:

• Sample preparation: Use freshly prepared cell or tissue lysates in a non-denaturing buffer. For brain tissue, gentle homogenization is crucial to preserve protein-protein interactions.

• Antibody amount: Use 0.5-4.0 μg of STAU1 antibody per 1.0-3.0 mg of total protein lysate .

• Precipitation method:

  • Protocol example: Incubate STAU1 antibody with Protein G magnetic beads for 10 minutes under agitation, then add cell lysate and incubate under agitation .

  • For RNA-preserving conditions (studying STAU1-RNA interactions), use RIP (RNA immunoprecipitation) protocols with RNase inhibitors.

• Controls: Include a no-antibody control or an isotype control to identify non-specific binding .

• Detection: Western blot analysis should show enrichment of STAU1 in the IP sample compared to input and negative controls.

• Co-IP applications: STAU1 immunoprecipitation can be used to study:

  • STAU1 self-association (as demonstrated in pull-down assays)

  • RNA-protein interactions (when combined with RT-PCR for specific transcripts)

  • Protein-protein interactions with translation factors or other RNA-binding proteins

What are the critical factors for successful immunofluorescence detection of STAU1?

For optimal STAU1 visualization by immunofluorescence:

• Fixation: Use 4% paraformaldehyde for 15-20 minutes at room temperature. Over-fixation can mask epitopes.

• Permeabilization: 0.1-0.5% Triton X-100 for 5-10 minutes is typically sufficient.

• Blocking: 5-10% normal serum (matched to secondary antibody host) with 1% BSA.

• Antibody dilution: Use STAU1 antibody at 1:200-1:800 dilution .

• Expected pattern: Endogenous STAU1 typically shows punctate distribution in the cytoplasm, with discrete small puncta visible in various cell types including COS7, HEK-293T, and neurological tumor cell lines .

• Co-localization studies: Consider co-staining for:

  • Stress granule markers (STAU1 is recruited to stress granules under stress conditions)

  • RNA granule components for dendritic transport studies

  • Translation factors to study STAU1's role in translation regulation

• Validation: The staining pattern should differ in cells with STAU1 knockdown or knockout, confirming specificity.

How can STAU1 antibodies be used to study liquid-liquid phase separation (LLPS) and stress granule formation?

STAU1 undergoes LLPS to form RNA-enriched condensates that regulate translation. To study this phenomenon:

• Visualization of STAU1 condensates:

  • Use immunofluorescence with STAU1 antibodies to visualize endogenous STAU1 condensates

  • Look for discrete small STAU1 puncta in the cytoplasm, as observed in various cell lines

  • Cell types with higher STAU1 levels (HepG2, SW1990, Caco-2) show significantly larger puncta sizes

• Stress granule association:

  • Induce stress granules with sodium arsenite, heat shock, or other stressors

  • Co-stain for STAU1 and stress granule markers (G3BP1, TIA-1)

  • STAU1 is recruited to stress granules under stress conditions in oligodendrocytes and hippocampal neurons

• LLPS dependency experiments:

  • Compare wild-type STAU1 with LLPS-deficient mutants (e.g., 5KE mutant described in literature)

  • The LLPS property of STAU1 is critical for its function in regulating RNA translation, as demonstrated by the inability of LLPS-deficient mutants to affect mTOR signaling

• Live cell imaging:

  • For dynamic studies of STAU1 condensates, combine fixed-cell immunofluorescence with STAU1 antibodies for endogenous protein detection and live-cell imaging with fluorescently-tagged STAU1

What experimental approaches can I use to investigate STAU1's role in neurodegenerative diseases?

STAU1 has been implicated in several neurodegenerative conditions, including spinocerebellar ataxia type 2 (SCA2) and potentially other disorders. To investigate this association:

• Expression analysis in disease models:

  • Use Western blot with STAU1 antibodies to quantify STAU1 levels in:

    • Patient-derived fibroblasts

    • Disease model cell lines (e.g., STHdh^Q111/Q111 Huntington's disease cells)

    • Brain tissue from animal models or post-mortem human samples

  • Research has shown STAU1 elevation in cells from SCA2 patients, ALS patients, and SCA2 mouse models

• Co-localization with disease-related proteins:

  • Perform immunofluorescence co-staining of STAU1 with disease-associated proteins

  • STAU1 has been shown to be recruited to mutant ATXN2 aggregates in brain tissue from SCA2 patients and in a SCA2 mouse model

• Functional studies:

  • Manipulate STAU1 levels (knockdown/overexpression) in disease models and assess effects on:

    • Protein aggregation

    • Autophagy function

    • mTOR signaling (STAU1 condensate promotes mTOR translation)

    • Disease-related phenotypes

  • Research has shown that reduction of Stau1 in vivo improved motor behavior in a SCA2 mouse model and reduced aggregation of polyglutamine-expanded ATXN2

• mTOR signaling analysis:

  • STAU1 LLPS promotes mTOR translation, leading to mTOR hyperactivation and autophagy-lysosome dysfunction in neurodegenerative disease models

  • Interference with STAU1 condensate formation normalizes mTOR levels and ameliorates autophagy-lysosome function

How can I design experiments to analyze STAU1-mediated mRNA decay (SMD)?

STAU1-mediated mRNA decay (SMD) is a process where STAU1 binding to the 3'UTR of target mRNAs triggers their degradation. To study this process:

• Identification of STAU1 binding sites:

  • Perform RNA immunoprecipitation (RIP) using STAU1 antibodies followed by sequencing (RIP-seq)

  • STAU1 binding sites (SBS) are typically located in double-stranded regions with high GC content

  • Different classes of SBS have been identified in various mRNA regions (5'UTR, coding sequence, 3'UTR)

• Analysis of target mRNA stability:

  • Measure half-life of candidate STAU1 target mRNAs in cells with normal vs. reduced/increased STAU1 levels

  • Use actinomycin D chase experiments to block transcription and monitor mRNA decay rates

  • STAU1 recruitment to the 3'UTR of target mRNA elicits the SMD pathway to promote RNA degradation

• Translation regulation studies:

  • STAU1 binding can have opposing effects depending on binding location:

    • Enhances translation when bound to 5'UTR or coding sequence

    • Promotes degradation or prevents translation when bound to 3'UTR

  • Use polysome profiling or ribosome profiling to assess translational status of STAU1 targets

• Structure-function analysis:

  • Compare effects of wild-type STAU1 with mutants defective in:

    • RNA binding (e.g., mutations in dsRBD3 and dsRBD4)

    • Self-association (e.g., mutations in dsRBD5 and dsRBD2)

    • LLPS (e.g., 5KE mutant)

  • Both the LLPS and RNA-binding properties of STAU1 are required for its function in regulating RNA translation

What are the considerations for studying STAU1 self-association in research?

STAU1 has been shown to self-associate through both RNA-dependent and protein-protein interaction mechanisms. To investigate this property:

• In vitro approaches:

  • His-tag pull-down assays: Use bacterially expressed his-tagged STAU1 to pull down in vitro synthesized ^35S-labeled STAU1

  • Include RNase treatment (50 μg/mL) to distinguish RNA-dependent from direct protein-protein interactions

• Live cell approaches:

  • Bioluminescence resonance energy transfer (BRET) assays with STAU1 fused to appropriate donor and acceptor tags

  • Co-immunoprecipitation of differently tagged STAU1 proteins

• Domain mapping:

  • The double-stranded RNA-binding domains dsRBD3 and dsRBD4 contribute to self-association through RNA binding

  • Protein-protein interactions also occur via dsRBD5 and dsRBD2

  • Generate and test domain deletion mutants:

    • Stau1 Δ3-YFP (deletion of dsRBD3)

    • Stau1 Δ4-YFP (deletion of dsRBD4)

    • Point mutations in RNA-binding domains:

      • Stau1 KK-YFP (mutations in dsRBD3)

      • Stau1 4K-YFP (mutations in both dsRBD3 and dsRBD4)

• Functional consequences:

  • Self-association may be important for STAU1's ability to form higher-order RNA-protein complexes

  • It may contribute to STAU1's phase separation properties and condensate formation

  • Mutants defective in self-association can be used to study the role of multimerization in STAU1's various functions

What are common issues when using STAU1 antibodies and how can they be resolved?

What critical controls should be included in STAU1 antibody-based experiments?

For Western blotting:

• Positive controls: Human brain tissue, K-562 cells, mouse brain tissue

• Negative controls: STAU1 knockdown or knockout samples

• Loading controls: Standard housekeeping proteins (β-actin, GAPDH, etc.)

• Molecular weight markers: To confirm detection at expected sizes (55 kDa and 63 kDa)

For immunoprecipitation:

• Input sample (5-10% of starting material)

• No-antibody control or isotype control antibody

• STAU1 knockdown samples to demonstrate specificity

• Western blot validation of immunoprecipitated material

For immunofluorescence:

• Secondary antibody-only control

• STAU1 knockdown cells

• Co-staining with organelle markers to confirm subcellular localization

• Peptide competition (pre-incubation of antibody with immunizing peptide)

For RNA immunoprecipitation:

• Non-specific IgG control

• Input RNA sample

• Non-target RNA controls

• DNase treatment to eliminate DNA contamination

• RT-minus controls for PCR

How can I ensure reproducibility when using STAU1 antibodies across different experimental systems?

To maintain consistent results when using STAU1 antibodies:

• Antibody validation in each system:

  • Verify antibody specificity in each new cell line or tissue type

  • Validate by Western blot before using for other applications

  • Document lot-to-lot variability by testing new lots against previous ones

• Standardized protocols:

  • Maintain detailed protocols with exact buffer compositions

  • Use consistent antibody dilutions and incubation times

  • Document any modifications for specific applications

• Quantification and normalization:

  • Use appropriate loading controls for Western blots

  • For immunofluorescence, employ consistent exposure settings and quantification methods

  • Normalize STAU1 levels to reference genes or proteins appropriate for your experimental system

• Inter-laboratory validation:

  • Compare antibody performance with published results

  • Consider using recombinant STAU1 antibodies for improved lot-to-lot consistency

  • Document antibody catalog numbers and lot numbers in publications

• Controls for different STAU1 isoforms:

  • Be aware that antibodies may detect different STAU1 isoforms with varying efficiency

  • The calculated molecular weight of STAU1 is 63 kDa, but observed weights range from 55-65 kDa

  • Record which isoforms are detected in your experimental system

How can STAU1 antibodies be used to investigate the role of STAU1 in cancer biology?

Recent research suggests STAU1 may have roles in cancer progression. To investigate this connection:

• Expression analysis across cancer types:

  • Use Western blotting with STAU1 antibodies to compare STAU1 levels in cancer vs. normal tissues

  • Research has shown significantly higher STAU1 levels in certain cancer cell lines (HepG2, SW1990, Caco-2) compared to other cell types

• Correlation with cancer phenotypes:

  • Analyze relationship between STAU1 expression and:

    • Patient survival (some research suggests high STAU1 expression confers longer recurrence-free survival in non-small cell lung cancer)

    • Tumor stage and grade

    • Treatment response

• Mechanism investigation:

  • STAU1 condensate formation and mTOR regulation:

    • Cancer cells with higher STAU1 levels show larger STAU1 puncta sizes

    • These cells also exhibit elevated mTOR and p-mTOR levels

    • Study how STAU1-mediated mTOR regulation affects cancer cell growth and metabolism

• Target gene identification:

  • Use RNA immunoprecipitation with STAU1 antibodies followed by sequencing to identify cancer-relevant STAU1 target mRNAs

  • For example, STAU1 has been shown to promote THBS1 mRNA degradation in non-small cell lung cancer

• Therapeutic potential:

  • Test effects of STAU1 knockdown/knockout on cancer cell phenotypes

  • Investigate whether modulating STAU1 condensate formation affects cancer cell survival and proliferation

What are the latest methods for studying STAU1's role in the autophagy-lysosome pathway?

Recent research has revealed STAU1's involvement in regulating autophagy through mTOR signaling. To investigate this:

• Autophagy flux assessment:

  • Use LC3B-II and p62 Western blotting with STAU1 antibodies to correlate STAU1 levels with autophagy markers

  • Employ RFP-GFP-LC3B reporter assays to assess autophagosome/autolysosome ratio in cells with different STAU1 levels

  • Research has shown that STAU1 overexpression increases yellow puncta (autophagosome) vs. red puncta (autolysosome) ratio, indicating impaired autophagy

• Lysosomal function analysis:

  • Measure lysosomal acidification using LysoTracker or LysoSensor in cells with different STAU1 levels

  • STAU1 overexpression decreases fluorescence intensity of lysosomal dyes, indicating impaired acidification

  • This effect depends on STAU1's LLPS property, as LLPS-deficient mutants don't impair acidification

• TFEB localization studies:

  • Use immunofluorescence to track nuclear translocation of TFEB (master regulator of lysosomal biogenesis)

  • STAU1 overexpression impairs TFEB nuclear translocation, while STAU1 depletion restores it

• mTOR signaling assessment:

  • Monitor phosphorylation of mTOR targets (4E-BP1, S6K1) in relation to STAU1 levels

  • STAU1 depletion reduces phosphorylation levels of mTOR, 4E-BP1, and S6K1

• Rescue experiments:

  • Test whether mTOR inhibitors (rapamycin, Torin1) can rescue autophagy defects in cells with high STAU1 levels

  • Compare effects of wild-type vs. LLPS-deficient STAU1 mutants on autophagy markers